NCT04840355View on ClinicalTrials.gov

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

November 14, 2025

Study Completion Date

November 14, 2025

Conditions

Immune Related Adverse EventsPD-1

Interventions

DRUG

Sintilimab Injection

The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Guohui Li

OTHER